Associate Professor Naomi Allen
- Adiposity, body fat distribution and risk of cancer in UK Biobank
- Hormones, growth factors and health outcomes in middle and old age: a PheWAS approach in UK Biobank
- Proteomics and prostate cancer: Assessing the role of inflammation in the development of aggressive prostate cancer
- The extent of multi-morbidity in cancer patients in diverse populations
BSc, MSc, DPhil
Professor in Epidemiology
- Clinical Trial Service Unit
Naomi Allen is a Professor in Epidemiology, based in the Clinical Trial Service Unit and Epidemiological Studies Unit. She has worked predominantly on large-scale prospective studies such as EPIC and the Million Women Study and has a keen research interest in the role of diet, hormones and circulating biomarkers in cancer development. She is co-Principal Investigator of the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group, which aims to conduct individual pooled analyses of the relationship between circulating biomarkers and prostate cancer risk from cohort studies from around the world. In 2011, she became Senior Epidemiologist for UK Biobank and helps co-ordinate record linkage of routine health-related datasets into the study.
Hormone-related diseases and prostate cancer: an English national record linkage study.
Watts EL. et al, (2019), Int J Cancer
BODY SIZE AND COMPOSITION IN RELATION TO RISK OF ENDOMETRIAL CANCER IN UK BIOBANK
Omiyale W. et al, (2019), JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 73, A15 - A16
High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium.
Peres LC. et al, (2019), Cancer Res
C-reactive protein and ovarian cancer risk: Results from the Ovarian Cancer Cohort Consortium
ALLEN N., (2019), Cancer Research
The advantages of UK Biobank's open access strategy for health research.
Conroy M. et al, (2019), J Intern Med